Accordingly, other IAPs overexpressed in cancers, such as XIAP or survivin, are considered as potential therapeutic targets, despite they are also expressed in normal tissues (Fukuda and Pelus, 2006; LaCasse et al, 2006). The gene discussed is BIRC5; the disease is cancer.